Yes, brain health data is becoming a significant consumer privacy issue—and the implications extend far beyond typical medical privacy concerns. Unlike traditional health data, which reveals what someone has, brain health information reveals who someone is: their thoughts, memories, personality traits, and cognitive status. This neurological data, collected through wearable devices, brain imaging studies, cognitive monitoring apps, and clinical assessments for dementia, is increasingly attractive to insurers, employers, and data brokers while remaining poorly protected by existing privacy frameworks.
The privacy risk is concrete. A person wearing a cognitive monitoring wearable device may unwittingly generate data about early memory loss, executive function decline, or other neurological changes—information that could be used to deny insurance, disqualify someone from employment, or feed algorithmic decisions about their care. Unlike genetic data, which has at least some legal protections under GINA and other regulations, brain health data exists in a regulatory gray zone where it may not qualify for traditional HIPAA protections if collected outside clinical settings.
Table of Contents
- What Makes Brain Health Data Different From Other Medical Information?
- Current Regulatory Gaps and Why Existing Protections Fall Short
- Specific Privacy Risks in Dementia and Cognitive Care
- How Brain Health Data Could Be Misused in Insurance and Employment Decisions
- The Challenge of Informed Consent and Data Literacy
- Emerging Regulatory Responses and Neurorights Frameworks
- What Dementia Care Providers and Patients Can Do Now
What Makes Brain Health Data Different From Other Medical Information?
Brain health data is uniquely sensitive because it directly reflects mental capability, personality, and identity in ways that other medical records do not. A blood pressure reading indicates cardiovascular health; brain health data indicates how someone thinks, remembers, and functions cognitively. A cognitive assessment showing early memory loss or processing speed decline can infer depression, anxiety, personality traits, and future employability—information far more intimate than a diabetes diagnosis.
The problem is compounded by the sheer volume of data collection happening outside traditional medical settings. Fitness wearables with brain health monitoring features, apps that track sleep quality and cognitive function, smartwatches that measure EEG patterns, and home-based cognitive training programs all generate neurological data about users. Many of these devices and apps are consumer products with privacy policies that allow data sharing with third parties, research institutions, or AI companies building neural models. Someone using a commercially available sleep tracker to monitor their sleep disruption pattern may not realize the device is also logging biomarkers correlated with early cognitive decline—data that could be monetized or shared without explicit informed consent.
Current Regulatory Gaps and Why Existing Protections Fall Short
HIPAA, the primary federal health privacy law in the United States, only covers “covered entities” like hospitals, clinics, and health insurers. A person monitoring their memory loss through a consumer app or wearable device is not receiving care from a covered entity—they are using a commercial product. That data is largely unprotected by HIPAA. State privacy laws like California’s CPRA and Virginia’s VCDPA provide some rights to consumer data, but they treat all personal information equally and do not include neurotechnology-specific protections.
The FDA has recently begun regulating some software-based cognitive assessment tools and neurotechnology devices as medical devices, which would bring them under regulatory oversight. However, this approach creates a bifurcated market: clinically validated brain health tools face FDA scrutiny and HIPAA protections, while wellness and consumer-grade equivalents do not. A clinical memory assessment tool used in a research study may be regulated; the nearly identical app available on a smartphone is not. This gap allows data from unregulated devices to proliferate while the privacy protections only apply to formal clinical settings.
Specific Privacy Risks in Dementia and Cognitive Care
dementia diagnosis and care create particularly acute privacy risks because cognitive status is tightly linked to autonomy, dignity, and social stigma. A person with early cognitive impairment may not fully understand the implications of sharing their brain health data when enrolling in a telehealth cognitive screening or using a home monitoring device prescribed by their neurologist. Once shared, that data creates a permanent record of cognitive decline that could influence decisions about long-term care, guardianship, or eligibility for services.
In dementia research and clinical trials, brain health data collection is essential—but it is increasingly linked to genetic data, imaging, and behavioral records that together paint a complete neurological profile. Researchers may promise that data is de-identified, but the combination of cognitive metrics, neuroimaging results, and demographic information can often re-identify individuals, particularly in smaller studies or rare disease populations. An Alzheimer’s research participant whose brain MRI, amyloid biomarkers, and cognitive test scores are shared with an AI company building early-detection algorithms may later discover that an insurer obtained the data and used it to deny coverage based on predictive cognitive risk.
How Brain Health Data Could Be Misused in Insurance and Employment Decisions
Insurance companies have long sought genetic information to stratify risk, and brain health data represents a new frontier for risk assessment. If an insurer learns that an applicant has cognitive changes associated with increased dementia risk, they could use that information to deny coverage, increase premiums, or exclude memory-related conditions. Similarly, life insurance companies could use cognitive decline markers to assess longevity risk. While explicit genetic discrimination is illegal under GINA, neurotechnology-derived cognitive markers are not explicitly protected—the law was written before brain health wearables existed.
Employment discrimination based on cognitive status is less visible but equally concerning. A manager who learns that an employee is using a cognitive monitoring app and that the data shows early decline could discriminate in promotion, assignment, or termination decisions, particularly in jobs where cognitive performance is valued. Unlike physical disability, cognitive status triggers cultural assumptions about competence and future capability. An employee with subtle memory loss who is performing well may be relegated to less demanding work or pushed out entirely based on data that does not reflect their current functional ability. The employee may not even know their cognitive data was accessed or that it influenced employment decisions.
The Challenge of Informed Consent and Data Literacy
Most consumers do not understand what brain health data reveals or what risks it carries. Privacy policies for wearables and apps are lengthy, use legal language, and often reserve the right to share data with third parties for research or commercial purposes. A person downloading a sleep tracking app to monitor sleep disruption may not read the privacy policy at all, and if they do, they may not grasp that the app’s sleep architecture analysis is inferring cognitive status or that the data could be shared with sleep research companies, pharmaceutical manufacturers, or insurance actuaries.
Informed consent for brain health data collection is further complicated by the fact that the risks of data misuse evolve over time. A person who agrees to share their cognitive data with a research institution today does not know what algorithms will exist in five years or how future employers and insurers will access and use that data. The concept of “dynamic consent,” where people maintain control over their data and can withdraw or restrict sharing, remains rare in practice—most consent is one-time and covers future uses the person cannot anticipate.
Emerging Regulatory Responses and Neurorights Frameworks
Some countries and jurisdictions are beginning to create neurotechnology-specific regulations. The European Union, which already has stronger data protection frameworks under GDPR, is developing guidance on “neurorights”—fundamental rights specific to neurotechnology that include mental privacy, cognitive liberty, and psychological continuity. These concepts recognize that brain health data is categorically different from other medical information and requires heightened protections.
In the United States, there is no federal neurorights framework, but some bioethicists, neurologists, and patient advocates are pushing for one. The concept includes the right to know what inferences are being made about one’s brain, the right to refuse neurological data collection, and the right to cognitive liberty—freedom from unwanted or unethical manipulation of one’s neural information. However, translating these philosophical principles into law and regulation remains difficult, particularly because brain health monitoring happens across multiple domains (clinical, research, wellness, workplace) with different regulatory homes and stakeholders.
What Dementia Care Providers and Patients Can Do Now
Until comprehensive regulations exist, dementia care providers and patients should treat brain health data as highly sensitive. For providers, this means: carefully vetting any digital tools or wearables before recommending them to patients, ensuring that data collection and sharing terms are transparent and minimal, and documenting what data is collected and how it will be protected. For patients and families, this means: reading privacy policies for any app or device before use, asking clinicians explicitly what data is being collected and whether it will be shared, requesting data deletion or limiting data access whenever possible, and being cautious about enrolling in research studies that involve broad data-sharing provisions unless the research addresses a pressing clinical need.
Specifically, any cognitive assessment tool recommended by a neurologist or dementia care clinic should be HIPAA-covered or have explicit contractual protections against data sharing with insurers, employers, or for-profit data brokers. Wearable devices used for clinical monitoring (as opposed to wellness tracking) should have clear data governance agreements. If a research study involving brain health data asks for consent, the consent form should specify exactly who will have access to the data, for how long, and under what circumstances data may be re-shared or used for secondary purposes.
- —
